The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.本發明提供了抗VEGF抗體，將該抗VEGF抗體配製為適合於注射、特別地玻璃體內注射的高濃度的、水性藥物組成物。該水性藥物組成物可用於將高濃度的抗體活性成分遞送至患者，而不出現高水平的抗體聚集以及高水平的亞可見微粒物質。本發明之水性組成物包含濃度為至少50mg/ml的抗體。本發明的水性藥物組成物包含糖、緩衝劑、以及表面活性劑。
